Donor plasma (in the TPE replacement context)

human tissue

provenance:human tissue

first introduced:2024

regulatory status:off label

context:Donor plasma in the TPE-IVIG protocol refers to the standardized replacement fluid (typically albumin in saline) returned to the patient after plasma removal during therapeutic plasma exchange. The Circulate protocol described in the *Aging Cell* trial does not transfuse fresh young donor plasma; the older 'young plasma' protocols (Ambrosia and successor companies) used fresh donor plasma directly and are a related but distinct category. The Circulate protocol's biological action, in the proposed mechanism, derives from the removal of aged recipient plasma rather than from the infusion of young donor plasma per se. The distinction matters: FDA has issued consumer warnings specifically against the 'young plasma' fresh-donor model, while standard albumin-based TPE retains its FDA approval for autoimmune neurological and hematologic indications.

MECHANISM CLAIMED

Removal of aged recipient plasma, with replacement by albumin in saline, reduces circulating inflammatory and senescence-associated factors and induces a systemic rejuvenation response measurable across the immune and inflammatory domains of the multi-omics panel.

MECHANISM ACTUAL

Removal of aged plasma during apheresis does reduce circulating levels of inflammatory mediators and immunoglobulins acutely; the *Aging Cell* trial reports concurrent reductions on a panel of 35 epigenetic clocks (most pronounced in immune and inflammatory Systems Age domains). Whether this translates into durable biological-age reduction beyond the immediate post-treatment window, and whether it produces meaningful hard-endpoint clinical benefit (mortality, disease incidence, functional capacity), is unestablished. The single trial is short (six sessions over approximately three months), small (N=42), single-blind, and carries a disclosed conflict of interest (the investigators are members of the commercializing company Circulate, Inc.; the paper states it received no specific funding); independent replication is not published.

INTERVENTIONS USING IT

Therapeutic plasma exchange with intravenous immunoglobulin (TPE-IVIG)

NOTES

Donor plasma in the TPE-IVIG context is the standard replacement fluid (typically 5 percent albumin in saline) returned to the patient after plasma removal during apheresis. The biologically active step in the proposed mechanism is the removal of aged recipient plasma, not the infusion of young donor plasma. The Circulate protocol is therefore distinct from the ‘young plasma’ category (Ambrosia and successors) against which the FDA has issued explicit consumer warnings, although both share the underlying premise that something in the plasma of older recipients drives aging-related decline.